古风,旷世神医

成纖維細(xì)胞生長(zhǎng)因子23(FGF23)單克隆抗體

Monoclonal Antibody to Fibroblast Growth Factor 23 (FGF23)

ADHR; HYPF; HPDR2; PHPTC; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor

編號(hào)MAA746Hu23
物種Homo sapiens (Human，人)相同的名稱，不同的物種。
來(lái)源單抗制備
宿主小鼠
效價(jià)(克隆號(hào))8-2#
Ig亞型 IgG1 Kappa
純化方式蛋白A + 蛋白G親和純化
標(biāo)記物無(wú)標(biāo)記物
免疫原RPA746Hu01-成纖維細(xì)胞生長(zhǎng)因子23(FGF23)重組蛋白
緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
性狀液體
濃度1mg/mL
且適物種-
應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見(jiàn)流式抗體。
下載英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
規(guī)格20μl100μl200μl1ml10ml
價(jià)格¥ 6141432¥ 1432¥ 2046¥ 5115¥ 20460
欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!

產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)

AF488 staining on IF;
Sample: SH-SY5Y cell
Primary Ab: 20μg/ml Mouse Anti-Human FGF23 Antibody
Second Ab: 2μg/ml AF488-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu11)

通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證

特異性

該抗體是針對(duì)FGF23的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別FGF23。

用法

Western blotting: 0.01-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.

儲(chǔ)存

經(jīng)常使用則4°C保存。-20°C保存不超過(guò)兩年。避免反復(fù)凍融。

穩(wěn)定性

熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。

贈(zèng)品

增值服務(wù)

抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
 細(xì)胞和組織染色液
 抗體陽(yáng)性對(duì)照品
 組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
 DAB顯色試劑盒
 SABC試劑盒
 長(zhǎng)臂生物素標(biāo)記試劑盒
 實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)

相關(guān)產(chǎn)品

編號(hào)	適用物種：Homo sapiens (Human，人)	應(yīng)用(僅供研究使用，不用于臨床診斷！)
RPA746Hu01	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)重組蛋白	Positive Control; Immunogen; SDS-PAGE; WB.
RPA746Hu02	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)重組蛋白	Positive Control; Immunogen; SDS-PAGE; WB.
RPA746Hu03	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)重組蛋白	Positive Control; Immunogen; SDS-PAGE; WB.
APA746Hu03	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)活性蛋白	Cell?culture;?Activity?Assays.
RPA746Hu04	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)重組蛋白	Positive Control; Immunogen; SDS-PAGE; WB.
APA746Hu01	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)活性蛋白	Cell?culture;?Activity?Assays.
PAA746Hu02	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)多克隆抗體	WB,IHC.
PAA746Hu03	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)多克隆抗體	WB; IHC; ICC; IP.
PAA746Hu04	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)多克隆抗體	WB
PAA746Hu01	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)多克隆抗體	WB; IHC; ICC; IP.
LAA746Hu71	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)多克隆抗體(生物素標(biāo)記)	WB; IHC; ICC.
RAA746Hu21	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)重組抗體	WB; IF; ICC; IHC; IP; FCM.
MAA746Hu23	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)單克隆抗體	WB; IHC; ICC; IP.
MAA746Hu22	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)單克隆抗體	WB; IHC; ICC; IP.
MAA746Hu21	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)單克隆抗體	WB
LAA746Hu72	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)單克隆抗體(生物素標(biāo)記)	WB; IHC; ICC.
MEA746Hu	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本)	Enzyme-linked immunosorbent assay for Antigen Detection.
SEA746Hu	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)	Enzyme-linked immunosorbent assay for Antigen Detection.
LMA746Hu	成纖維細(xì)胞生長(zhǎng)因子23(FGF23)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)	FLIA Kit for Antigen Detection.

參考文獻(xiàn)

雜志	參考文獻(xiàn)
Journal of international medicine	Prognostic impact of renal function in precapillary pulmonary hypertension[Pubmed: 24011362]
BMC Nephrology	FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients[Pubmed: 24180481]
Journal of Clinical Densitometry	Lower Fibroblast Growth Factor 23 Levels in Young Adults With Crohn Disease as a Possible Secondary Compensatory Effect on the Disturbance of Bone and Mineral Metabolism[Pubmed: 23623649]
J Intern Med.	Prognostic impact of renal function in precapillary pulmonary hypertension.[Pubmed:24011362]
Journal of Bone and Mineral Research	Adverse effects of osteocytic constitutive activation of ?-catenin on bone strength and bone growth[Pubmed:25639729]
Nefrologia	Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation El factor de crecimiento fibroblástico está asociado con el índice de masa ventricular izquierda, anemia y niveles bajos de saturación de la transferrina[PubMed: 26394828]
Medicine (Baltimore)	An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic Cancer[PubMed: 26266370]
Ann Biol Clin (Paris)	Les biomarqueurs des calcifications vasculaires: quelles limites analytiques pour leur transfert de la recherche bioclinique à la pratique?[PubMed: 26069069]
Scandinavian Journal of Gastroenterology	High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23[Pubmed:27326766]
PLOS?ONE	Prostaglandin-E2?Mediated?Increase?in?Calcium?and?Phosphate?Excretion?in a?Mouse?Model?ofDistal?Nephron?Salt?Wasting.[pubmed:27442254]
Journal of Laboratory Diagnostics	Evaluation of concentration fibroblast growth factor FGF-23 in hemodialysed patients and after kidney transplantation[publication:312592751]
Journal of Integrative Nephrology & Andrology	Associations between serum fibroblast growth factor 23 level and intradialytic hypotension in hemodialysis patients[issn:2394-2916]
Journal of Renal Nutrition	ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder.[pubmed:29056164]
Experimental Biology and Medicine(Maywood)	Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats[Pubmed:29763365]
Psychiatry Research	Cerebrospinal fluid FGF23 levels correlate with a measure of impulsivity[Pubmed:29677623]
BMC?Pediatrics	Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children[Pubmed:29907141]
Medical Science Monitor	Effect of Salt Intervention on Serum Levels of Fibroblast Growth Factor 23 (FGF23) in Chinese Adults: An Intervention Study[Pubmed:29608553]
International Journal of Chronic Obstructive Pulmonary Disease	Disconnection of pulmonary and systemic arterial stiffness in COPD[Pubmed:29881265]
Saudi?journal of?kidney?diseases and transplantation	Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patients[Pubmed:29970732]
Nephrology Dialysis?Transplantation	High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease[Pubmed: 30189026]
BioFactors?	Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma[Pubmed: 30334297]
Biological?Trace?Element?Research	Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients[Pubmed: 30847765]
Clin Implant Dent Relat Res.	Evaluation of FGF‐23 and 25(OH)D3 levels in peri‐implant sulcus fluid in peri‐implant health and diseases[Pubmed: 31407857]
JACC-Cardiovascular Imaging	PREVALANCE AND PROGRESSION OF CARDIOVASCULAR CALCIFICATIONS IN HAEMODIALYSIS PATIENTS[Pubmed: 28797410]
Saudi J Kidney Dis Transpl	Serum fibroblast growth factor 23 levels do not correlate with carotid intima-media thickness in patients with chronic kidney disease[Pubmed: 31696838]
Biomedicine & Pharmacotherapy	MiRNA-192-5p attenuates airway remodeling and autophagy in asthma by targeting MMP-16 and ATG7[Pubmed: 31918268]
	Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?[]
	THE RELATIONSHIP BETWEEN ARTERIAL STIFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS[]
	THE RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS KRON?K ?-[]
Calcif Tissue Int	The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations[Pubmed:35665817]
European Journal of Medical Genetics	Genetic and clinical profile of patients with hypophosphatemic rickets[Pubmed:35738466]
African Health Sciences	Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease[]